The study suggests that metronomic dosing of topotecan can reduce
prostate cancer growth at drug concentrations far below those that can be toxic to healthy cells in the body.
Given the limited treatment options for late-stage prostate
cancer and clinical use of topotecan, new clinical trials could occur in the near future, Arnold said.
The same research team is now studying the dosing effects of topotecan in breast cancer models.